I just received this write-up from a newsletter pu
Post# of 86974
(Total Views: 227)
Posted On: 10/26/2018 3:53:18 PM
I just received this write-up from a newsletter put out by Ray Blanco. Interesting.
This Biotech Is Hot
Last week I was traveling outside the U.S. evaluating potential medical cannabis opportunities abroad. From what I am seeing, massive new opportunities are about to break through in not just the U.S. and Canada, but also new regions as the world warms up to the medicinal potential of the cannabis plant.
Finding wins in the broader market is getting more difficult. A broad selloff like what we saw over the past week or so took every sector with it.
But I like biotech’s chance to bounceback a lot more than other sectors right now.
In May I suggested my followers consider a move on Merck (NYSE: MRK). At the time I was tracking developments of one of its cancer drugs, Keytruda.
Initial clinical trials were promising and Merck was vying for an FDA priority review consideration, which they received earlier in September.
Additionally, Merck may be entertaining a spinoff that would give it a prominent foothold in the cannabis processing market.
Your editor Sean McCloskey divulged this info to me, after sitting down to lunch with the Segment Marketing Manager of MillaporeSigma (a division of Merck), at of all places, a marijuana investors conference in Toronto this past August.
Whether we see a pot spinoff from Merck one day is anyone’s guess, but based on the dots we can connect, there’s a betting man’s chance we do.
Since we first suggested Merck in May shares are up over 18%. This even after the market’s broad selloff the past two weeks. Clearly there are strong tailwinds at work.
If their drug Keytruda successfully navigates the final stages of the FDA gauntlet, the gains from this revenue stream should help boost shares.
And if my suspicions are correct that a Merck is planning a cannabis spinoff venture, their shares could really run higher.
Ray Blanco (TechProfitsDaily@p.sevenfigurepublishing.com)
This Biotech Is Hot
Last week I was traveling outside the U.S. evaluating potential medical cannabis opportunities abroad. From what I am seeing, massive new opportunities are about to break through in not just the U.S. and Canada, but also new regions as the world warms up to the medicinal potential of the cannabis plant.
Finding wins in the broader market is getting more difficult. A broad selloff like what we saw over the past week or so took every sector with it.
But I like biotech’s chance to bounceback a lot more than other sectors right now.
In May I suggested my followers consider a move on Merck (NYSE: MRK). At the time I was tracking developments of one of its cancer drugs, Keytruda.
Initial clinical trials were promising and Merck was vying for an FDA priority review consideration, which they received earlier in September.
Additionally, Merck may be entertaining a spinoff that would give it a prominent foothold in the cannabis processing market.
Your editor Sean McCloskey divulged this info to me, after sitting down to lunch with the Segment Marketing Manager of MillaporeSigma (a division of Merck), at of all places, a marijuana investors conference in Toronto this past August.
Whether we see a pot spinoff from Merck one day is anyone’s guess, but based on the dots we can connect, there’s a betting man’s chance we do.
Since we first suggested Merck in May shares are up over 18%. This even after the market’s broad selloff the past two weeks. Clearly there are strong tailwinds at work.
If their drug Keytruda successfully navigates the final stages of the FDA gauntlet, the gains from this revenue stream should help boost shares.
And if my suspicions are correct that a Merck is planning a cannabis spinoff venture, their shares could really run higher.
Ray Blanco (TechProfitsDaily@p.sevenfigurepublishing.com)
(3)
(0)